Pharma BD Deal Intelligence
The 2005 Yamanouchi-Fujisawa merger built Astellas into a durable top-20 global pharma, though it now faces a real Xtandi patent-cliff test of that legacy.
Full analysis, sources & comparables →Japan's mid-tier pharmaceutical sector entered a wave of consolidation, with Yamanouchi-Fujisawa cited as the catalyst deal that forced Sankyo and Daiichi to…
Merger characterized as a 'merger of equals' combining Yamanouchi's urology/chemistry strengths with Fujisawa's transplant/immunology and fermentation…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Merger of equals announcement; formed Astellas Pharma April 1 2005; stock-swap
The 2005 Yamanouchi-Fujisawa merger built Astellas into a durable top-20 global pharma, though it now faces a real Xtandi patent-cliff test of that legacy.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. (this deal) | 2004 | $7.6B | 84 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2005 | — | 92 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Sanofi-Synthelabo SA / Aventis SA | 2004 | $65.0B | 80 |
| Genzyme Corporation / ILEX Oncology Inc. | 2004 | $1.0B | 66 |
| Hospira Inc. / Abbott Hospital Products Division | 2004 | — | 54 |
← Browse all deals · How we score deals
More: 2004 deals